Legato Capital Management LLC Buys Shares of 23,900 IDEAYA Biosciences, Inc. $IDYA

Legato Capital Management LLC bought a new stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) in the fourth quarter, Holdings Channel reports. The fund bought 23,900 shares of the company’s stock, valued at approximately $826,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Farther Finance Advisors LLC grew its position in shares of IDEAYA Biosciences by 171.1% during the 4th quarter. Farther Finance Advisors LLC now owns 919 shares of the company’s stock valued at $32,000 after acquiring an additional 580 shares during the period. Aster Capital Management DIFC Ltd purchased a new position in shares of IDEAYA Biosciences during the 3rd quarter valued at $38,000. ANTIPODES PARTNERS Ltd lifted its stake in IDEAYA Biosciences by 49.4% in the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,150 shares of the company’s stock worth $40,000 after purchasing an additional 380 shares in the last quarter. Abich Financial Wealth Management LLC purchased a new stake in IDEAYA Biosciences in the 3rd quarter worth $58,000. Finally, Global Retirement Partners LLC purchased a new stake in IDEAYA Biosciences in the 4th quarter worth $61,000. Institutional investors own 98.29% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on IDYA. Mizuho decreased their target price on shares of IDEAYA Biosciences from $52.00 to $50.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Guggenheim upped their target price on shares of IDEAYA Biosciences from $50.00 to $54.00 and gave the company a “buy” rating in a research report on Tuesday, April 14th. Wells Fargo & Company upped their target price on shares of IDEAYA Biosciences from $44.00 to $48.00 and gave the company an “overweight” rating in a research report on Tuesday, April 14th. Truist Financial set a $65.00 target price on shares of IDEAYA Biosciences in a research report on Monday, April 13th. Finally, Citigroup upped their price target on shares of IDEAYA Biosciences from $64.00 to $65.00 and gave the company a “buy” rating in a report on Thursday, February 19th. Fifteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $50.69.

Insider Activity

In other IDEAYA Biosciences news, Director Jeffrey Stein acquired 50,000 shares of the company’s stock in a transaction dated Monday, March 2nd. The shares were purchased at an average cost of $32.96 per share, for a total transaction of $1,648,000.00. Following the completion of the purchase, the director owned 54,281 shares in the company, valued at approximately $1,789,101.76. This trade represents a 1,167.95% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 4.70% of the company’s stock.

IDEAYA Biosciences Price Performance

Shares of IDYA stock opened at $29.10 on Tuesday. The company has a market capitalization of $2.56 billion, a P/E ratio of -18.19 and a beta of -0.04. The company’s 50-day simple moving average is $30.87 and its two-hundred day simple moving average is $32.79. IDEAYA Biosciences, Inc. has a one year low of $18.25 and a one year high of $39.28.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its earnings results on Tuesday, May 5th. The company reported ($1.11) EPS for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.04). The business had revenue of $6.56 million for the quarter, compared to analyst estimates of $5.04 million. During the same quarter in the prior year, the company earned ($0.82) EPS. IDEAYA Biosciences’s quarterly revenue was down 39.4% on a year-over-year basis. On average, research analysts expect that IDEAYA Biosciences, Inc. will post -4.28 EPS for the current fiscal year.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.